JP2014516964A - 治療用抗ｉｇｆ１ｒ合剤 - Google Patents

治療用抗ｉｇｆ１ｒ合剤 Download PDF

Info

Publication number
JP2014516964A
JP2014516964A JP2014511445A JP2014511445A JP2014516964A JP 2014516964 A JP2014516964 A JP 2014516964A JP 2014511445 A JP2014511445 A JP 2014511445A JP 2014511445 A JP2014511445 A JP 2014511445A JP 2014516964 A JP2014516964 A JP 2014516964A
Authority
JP
Japan
Prior art keywords
antibody
cdr
composition
inhibitor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014511445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516964A5 (cg-RX-API-DMAC10.html
Inventor
ゴーシユ，リリアン
シユー，カール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of JP2014516964A publication Critical patent/JP2014516964A/ja
Publication of JP2014516964A5 publication Critical patent/JP2014516964A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014511445A 2011-05-18 2012-05-15 治療用抗ｉｇｆ１ｒ合剤 Withdrawn JP2014516964A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161487452P 2011-05-18 2011-05-18
US61/487,452 2011-05-18
PCT/US2012/037864 WO2012158657A1 (en) 2011-05-18 2012-05-15 Therapeutic anti-igf1r combinations

Publications (2)

Publication Number Publication Date
JP2014516964A true JP2014516964A (ja) 2014-07-17
JP2014516964A5 JP2014516964A5 (cg-RX-API-DMAC10.html) 2015-07-16

Family

ID=47177305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511445A Withdrawn JP2014516964A (ja) 2011-05-18 2012-05-15 治療用抗ｉｇｆ１ｒ合剤

Country Status (6)

Country Link
US (1) US20140079665A1 (cg-RX-API-DMAC10.html)
EP (1) EP2709661A4 (cg-RX-API-DMAC10.html)
JP (1) JP2014516964A (cg-RX-API-DMAC10.html)
AU (1) AU2012255920A1 (cg-RX-API-DMAC10.html)
CA (1) CA2834566A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012158657A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150297613A1 (en) * 2011-12-13 2015-10-22 Servicio Andaluz De Salud Use of agents that alter the peritumoral environment for the treatment of cancer
ES2541870B1 (es) 2013-12-27 2016-05-12 Servicio Andaluz De Salud Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
EP3148547B1 (en) * 2014-06-02 2024-01-03 National Yang-Ming University Method for treating drug resistant cancer
CN110099680B (zh) 2016-10-11 2021-02-05 杜克大学 Er+乳腺癌的拉索昔芬治疗
US20180221476A1 (en) * 2017-02-06 2018-08-09 Oncoquest Nc. Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
CA3195512A1 (en) * 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス， インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
AU2023317484A1 (en) 2022-07-30 2025-03-13 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
WO2011057064A1 (en) * 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
US20130287763A1 (en) * 2010-07-28 2013-10-31 Merck Sharp & Dohme Corp. Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor

Also Published As

Publication number Publication date
CA2834566A1 (en) 2012-11-22
WO2012158657A1 (en) 2012-11-22
EP2709661A1 (en) 2014-03-26
US20140079665A1 (en) 2014-03-20
AU2012255920A1 (en) 2013-11-07
EP2709661A4 (en) 2015-01-28

Similar Documents

Publication Publication Date Title
US20140079665A1 (en) Therapeutic anti-igf1r combinations
EP2104501B1 (en) Methods of cancer treatment with igf1r inhibitors
AU2019416117B2 (en) CSF1R inhibitors for use in treating cancer
US8216571B2 (en) Fully human anti-VEGF antibodies and methods of using
JP2011140518A (ja) 癌を処置または予防するための方法および組成物
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
JP2019503674A5 (cg-RX-API-DMAC10.html)
MX2010012064A (es) Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
US20250025583A1 (en) Method of treatment of neuroendocrine tumors
KR20190085166A (ko) 항-ｖｅｇｆ 항체를 사용한 치료
WO2011057064A1 (en) Igf1r inhibitor based treatment of prostate cancer
US20220072166A1 (en) Method of treatment of neuroendocrine tumors
US20230338587A1 (en) Method of treating psma-expressing cancers
US20230321285A1 (en) Method of treating psma-expressing cancers
US8470297B1 (en) FDG-pet evaluation of Ewing's sarcoma sensitivity
HK1105151A1 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
HK1105151B (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150529

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20151217